Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

"The Adventure Jar," Showcases a Family Navigating the Challenges of a Cancer Diagnosis and Finding Magic in Time Together

ACCESS Newswire August 27, 2024

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire August 21, 2024

Gilead Sciences: "One of Best Employers for Women" by Forbes

ACCESS Newswire August 20, 2024

Building a Bridge to a Healthier World for Youth in Africa with Gilead Sciences

ACCESS Newswire August 20, 2024

Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Business Wire August 14, 2024

Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership To Help Address the Growing HIV Crisis in Eastern Europe and Central Asia

ACCESS Newswire August 13, 2024

Gilead Sciences Announces Second Quarter 2024 Financial Results

Business Wire August 8, 2024

Closing the HIV Diagnosis Gap in Germany with Gilead Sciences

ACCESS Newswire August 8, 2024

Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Business Wire July 25, 2024

Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

Business Wire July 25, 2024

Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024

Business Wire July 24, 2024

Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia

Business Wire July 22, 2024

Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025

Business Wire July 17, 2024

Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024

Business Wire July 16, 2024

Gilead Benefit Helps Employees Navigate Cancer Care

ACCESS Newswire July 1, 2024

Gilead's Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Business Wire June 20, 2024

Gilead and Kite Pharma Celebrates Pride Month

ACCESS Newswire June 19, 2024

New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment

Business Wire June 14, 2024

How Luciana Preger Is Helping Advance Gilead's Work in Oncology

ACCESS Newswire June 12, 2024

Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA

Business Wire June 6, 2024